Last updated 56 days ago
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
720 patients around the world
Available in United States, Chile, Argentina, Colombia, Brazil
Merck Sharp & Dohme LLC
14Research sites
720Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Non-Hodgkin Lymphoma
Small lymphocytic lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Av. Galvan 4102, CABA, Buenos Aireswww.cemic.edu.ar/
Av. Colón 3456, Mar del Plata, Buenos Aireshttp://iic-mardelplata.com.ar/
Perdriel 74, CABA, Buenos Aireshttps://www.hospitalbritanico.org.ar/
Av. Crámer 1180, CABA, Buenos Aires
Av. Dr. Arnaldo, 251 - Consolação, São Paulo - SP, 01255-090, Brazil
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
José Manuel Infante 805, Providencia, Región Metropolitana
StudyBELLWAVE-010
SponsorMerck Sharp & Dohme LLC
Conditions
Chronic lymphocytic leukemiaSmall lymphocytic lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05947851
